Department of Surgical Oncology, the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands.
Eur J Cancer. 2010 Mar;46(4):720-8. doi: 10.1016/j.ejca.2009.12.006. Epub 2010 Jan 13.
To evaluate the prognostic value of the tumour stroma ratio (TSR) in resected adenocarcinoma of the oesophagus.
In the literature, a refinement of oesophageal cancer staging has been proposed. Recently, TSR has been identified as a histological characteristic of the tumour itself that proved to be a strong predictor for survival in colorectal cancer.
In our cancer registry database, we identified 93 consecutive patients who underwent resection for oesophageal adenocarcinoma between 1990 and 2004 in two hospitals in our region. Using a predefined histopathological protocol, TSR was determined on the original haematoxylin-eosin (H&E) tissue sections of oesophagectomy specimens by two independent investigators.
With a cut-off value of 50% tumour/stroma, patients were classified as TSR high (n=60) or TSR low (n=33). There were no significant differences in patient, tumour and treatment characteristics between the two groups, except for M status (M1a) and radicality of resection. The (disease-free) survival in the TSR high group was significantly better than in the TSR low group. By multivariate analysis, TSR was identified as a highly significant prognostic factor for overall survival (HR 2.0; P=0.010), independent of depth of tumour invasion, nodal status, lymph node ratio, extracapsular involvement, TNM stage, histological grade and radicality of resection.
TSR is a new and practicable prognostic tumour characteristic for oesophageal adenocarcinoma that can discriminate patients with a poor outcome from those with a better outcome.
评估切除的食管腺癌中肿瘤间质比(TSR)的预后价值。
在文献中,提出了一种改良的食管癌分期方法。最近,TSR 被确定为肿瘤本身的组织学特征,在结直肠癌中被证明是生存的强有力预测因素。
在我们的癌症登记数据库中,我们确定了 93 例连续患者,他们在我们地区的两家医院于 1990 年至 2004 年间接受了食管腺癌切除术。使用预定的组织病理学方案,通过两位独立的研究人员在食管切除术标本的原始苏木精-伊红(H&E)组织切片上确定 TSR。
以 50%肿瘤/间质为截断值,患者被分为 TSR 高(n=60)或 TSR 低(n=33)组。两组之间在患者、肿瘤和治疗特征方面没有显著差异,除了 M 状态(M1a)和切除的根治性。TSR 高组的(无病)生存率明显优于 TSR 低组。通过多变量分析,TSR 被确定为总生存的高度显著预后因素(HR 2.0;P=0.010),独立于肿瘤浸润深度、淋巴结状态、淋巴结比率、包膜外侵犯、TNM 分期、组织学分级和切除的根治性。
TSR 是一种新的、可行的食管腺癌预后肿瘤特征,可以将预后不良的患者与预后较好的患者区分开来。